• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deal search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
      • Deals search
      • Exits search
      • Funds search
      • Sponsors search
      • Advisers search
      • LPs search
      • League tables
      • Reports
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
UNQUOTE
  • Nordics

Mimir Group ramps up global origination effort with London office and focus on life science carve-outs

Mimir Group ramps up global origination effort with London office and focus on life science carve-outs
Joakim Notö, Chairman and Managing Partner of Mimir Group
  • Min Ho
  • 26 May 2023
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

Carve-out specialist Mimir Group has recently opened its London office in a bid to ramp up its origination effort, including a push to target sectors including life sciences, group Chairman and Managing Partner Joakim NotУЖ said.

The Sweden-based perpetual investment company has so far placed one team member in London running its business development and deal origination, with the expectation of further London-based hires to oversee its deal origination and deal execution over the next few years, he said. Pierre Chapuis joined the London office from investment research group BCA Research and now helps run the firm's global business development, according to his LinkedIn profile.

"We want more deal flow as it can always be better," he said. "London is where a lot happens in banking and M&A."

Deals that Mimir is particularly keen on include life science groups, namely subsectors including veterinary drugs, specialty chemicals, diagnostics, generic drugs, software and services, and non R&D-heavy pharmaceuticals companies, he said.

"People typically think of the sector as high growth with high multiples, but they also tend to forget that there are mature areas in both life sciences and technology where you have businesses that are perhaps GDP-growth type companies which are non-core to an owner," he said.

Notö acknowledges that life sciences is quite "unusual for someone like us", but points to its team, which has a strong experience in the sector. This includes operations head and managing partner Jeff Bork, who has experience in running healthcare companies, according to the firm's website.

Searching for deals
Outside life science, it will also continue its search for engineering, defence, technology, manufacturing, business services, forestry-related products and distribution targets, he said. It has a global mandate to search for deals, including Germany, the UK and the Nordics, as well as the US, he added.

Mimir can deploy up to EUR 100m in equity in any deals that it makes through the perpetual investment company it has been running since last year. He declined to comment on the size of its balance sheet.

Backers for the new investment company include some of its former fund investors and new investors, he said. These include global institutions and private individuals, as well as large private companies from North America and Europe, he said.

Mimir Group was founded in 2016 after raising its first fund targeting special situations with the backing of three institutional investors, including Stockholm listed fund-of-funds Naxs [STO:NAXS], and more than half a dozen high net worth individuals, including a life sciences investor, as previously reported. The firm did not disclose the size of the vehicle.

Since its foundation, Mimir has acquired more than 15 companies, most of which were carved out from large corporations across industries in Europe and North America.

Carve-out considerations
In spite of the volatile markets, dealflow for carve-outs remains "more or less the same" to that of a good economy, he said.

"If you have a very good economy, there will be a lot of focus on carve-outs of underperformers because sellers want to focus their strategy where there is a lot of growth. Likewise, if you're in a poorly performing economy, some corporates may look at their underperformers to focus their strategy and focus on their core strengths," he said.

The macroeconomic outlook is also raising questions of "whether it's a good time or not" to sell some of its businesses, even though there are some potential divestment candidates in its portfolio, he said.

"We are a perpetual investment company. We could sell some businesses or we could hold them – it doesn't really matter to us," he said.

Mimir has a traditional three- to-seven year holding period for its companies, as previously reported.

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • Nordics
  • Healthcare
  • Industrials
  • Support services
  • People
  • UK / Ireland
  • DACH
  • Investments
  • Sweden
  • United Kingdom
  • people moves
  • Exclusive

More on Nordics

VC Spotlight: Climentum Capital fund to announce 10th investment this month; aims for final close at EUR 75m end-Sept
VC Spotlight: Climentum Capital fund to announce 10th investment this month; aims for final close at EUR 75m end-Sept

The GP expects to launch its second fund in 2025 with a target size of EUR 100m-EUR 125m

  • Nordics
  • 16 August 2023
Mimir Group ramps up global origination effort with London office and focus on life science carve-outs
Mimir Group ramps up global origination effort with London office and focus on life science carve-outs

Stockholm-based investor is considering divestments, although challenging market remains a barrier

  • Nordics
  • 26 May 2023
3i to invest in Danish children's brand Konges Sløjd
3i to invest in Danish children's brand Konges Sløjd

Deal aims to support the baby and children apparel group expand in Asia and the US

  • Nordics
  • 21 June 2022
HG-backed Visma to divest IT consulting unit to CVC
HG-backed Visma to divest IT consulting unit to CVC

Sponsor will invest in the carve-out from the Norwegian business software and IT provider via Fund VIII

  • Nordics
  • 16 June 2022

Latest News

Partners Group to release IMs for Civica sale in mid-September
  • Exits
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
BHM Group builds on PE strategy, eyes European medtech and renewable energy acquisitions
  • Investments
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Czech Republic-headquartered family office is targeting DACH and CEE region deals

  • 01 September 2023
Redalpine expands leadership team amid CHF 1bn-plus fundraise
  • Venture
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO

  • 31 August 2023
Change Ventures aims to hold final close for EUR 20m third fund by mid-2024
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds

  • 31 August 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013